MedTrace Logo

Hypofractionated SBRT For Prostate Cancer

NCT00977860 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2024-05-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed during a 24 month follow up and to estimate the rate of biochemical Disease-Free Survival, Phoenix and American Society for Therapeutic Radiology and Oncology definitions, at 2 years following hypofractionated stereotactic body radiation therapy for low and intermediate risk prostate cancer.

Conditions

Interventions

RADIATION

Stereotactic Body Radiation Therapy

36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period

Sponsors & Collaborators

  • Adam Olson

    lead OTHER

Principal Investigators

  • Adam Olson, MD · University of Pittsburgh Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-07
Primary Completion
2022-07-08
Completion
2022-07-08
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00977860 on ClinicalTrials.gov